Destiny Pharma
plc
("Destiny Pharma" or "the
Company")
Posting of Annual Report and
Accounts, and Notice of AGM
Brighton, United Kingdom - 9 May 2024
- Destiny Pharma plc (AIM: DEST) a clinical stage
innovative biotechnology company focused on the development of
novel medicines that can prevent life-threatening infections,
announces that the following documents are now available on the
Company's website at www.destinypharma.com:
· Annual
Report and Accounts of the Company for the year ended 31 December
2023
· Notice
of the 2024 Annual General Meeting ("AGM") and details for voting
by proxy, which is to be held at 11.00 a.m. on 12 June 2024 at the
offices of Covington & Burling LLP, 22 Bishopsgate, London,
EC2N 4BQ
Printed copies of both documents
will be posted to shareholders today.
Immediately following the AGM at
11:00am, Destiny Pharma will host a live presentation followed by
Q&A.
In order to ensure that shareholders
are able to follow the proceedings of the AGM without attending in
person, the Company will provide access online via the Investor
Meet Company platform. However, please note that shareholders will
not be able to vote online at the AGM via the platform and are
therefore requested to submit their votes via proxy, as early as
possible. Shareholders are invited to submit any questions for the
Board to consider. Questions can be pre submitted ahead of the AGM
via the Investor Meet Company Platform up until 9 a.m. the day
before the AGM or submitted at any time during the AGM
itself.
Shareholders that wish to attend the
AGM remotely should register for the event in advance by using the
following link:https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
For
further information, please contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
FTI
Consulting
Ben Atwell / Simon Conway / Michael
Trace
+44 (0) 203 727 1000
destinypharma@fticonsulting.com
Shore Capital (Nominated Adviser and Broker)
Daniel Bush / James Thomas / Lucy
Bowden
+44 (0) 207 408 4090
About Destiny Pharma
Destiny Pharma is an innovative,
clinical-stage biotechnology company focused on the development and
commercialisation of novel medicines that can prevent
life-threatening infections. The company's drug development
pipeline includes two late-stage assets: XF-73 nasal gel, a
proprietary drug targeting the prevention of post-surgical staphylococcal
hospital infections including MRSA and
NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.
difficile infection (CDI) recurrence which is the leading cause of
hospital acquired infection in the US.